浙江震元股份有限公司董事、高级管理人员 持有并买卖本公司证券的管理制度 （2025 年 11 月 28 日第十一届董事会 2025 年第五次临时会议通过修订） 第一条 根据《公司法》、《证券法》、《上市公司董事和高级管理 人员所持本公司股份及其变动管理规则》、《深圳证券交易所股票上市 规则》、《深圳证券交易所上市公司自律监管指引第 10 号——股份变动 管理》等法律、法规的规定,结合公司实际，制定本制度。 第二条 公司及其董事和高级管理人员，应当遵守本制度。 (五)深圳证券交易所要求的其他情形。 第六条 公司董事和高级管理人员委托公司董事会申报个人信息 后，深圳证券交易所根据其申报数据资料，对其身份证件号码项下开 立的证券账户中已登记的本公司股份予以锁定。 第三条 公司董事和高级管理人员所持本公司证券，是指登记在 其名下的所有本公司证券。公司董事和高级管理人员从事融资融券交 易的，还包括记载在其信用账户内的本公司股份。 第四条 公司董事和高级管理人员计划买卖本公司证券的，应当 在买卖前三个交易日内填写《买卖本公司证券问询函》（附件一）并提 交董事会, 由董事会秘书具体负责确认，但如拟通过集中竞价方式卖 出股票 ...

（2025 年 11 月 28 日第十一届董事会 2025 年第五次临时会议通过修订） 第一章 总则 第一条 为规范公司经营行为，控制经营风险，提高经济效益， 保障公司经营活动的健康发展，根据《中华人民共和国审计法》《中 华人民共和国审计法实施条例》《审计署关于内部审计工作的规定》 《企业内部控制基本规范》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》《公司章程》等国家有关法律、 法规，结合公司实际，制定本制度。 第二条 本制度所称内部审计，是指对本单位及所属单位财务收 支、经济活动、内部控制、风险管理实施独立、客观的监督、评价和 建议，以促进单位完善治理、实现目标的活动。 第三条 公司本级各部门、分公司、控股子公司，以及上述机构 相关责任人员，依照本制度接受审计、监督。 浙江震元股份有限公司内部审计制度 第四条 公司内部审计机构和内审人员应依法审计，坚持独立性 原则，公正客观、忠于职守、廉洁奉公、保守秘密；不得滥用职权、 营私舞弊、玩忽职守。 第二章 审计机构与人员 第五条 公司设内部审计机构，负责公司内部审计业务，接受公 司党委、董事会（或者主要负责人）的直接领导，承担审计委员 ...

浙江震元股份有限公司董事会提名委员会工作细则 （2025 年 11 月 28 日第十一届董事会 2025 年第五次临时会议通过修订） 第一章 总 则 第一条 为规范浙江震元股份有限公司（以下简称"公司"）董 事及高级管理人员的产生程序，完善公司治理结构，根据《中华人民 共和国公司法》、《上市公司治理准则》、《公司章程》及其他有关规定， 公司特设立董事会提名委员会，并制定本工作细则。 第二条 董事会提名委员会是董事会设立的专门工作机构，主要 负责对公司董事和高级管理人员的人选、选择标准和程序提出建议。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，独立董事占多数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一以上提名，并由董事会选举产生。 第五条 提名委员会设召集人一名，由独立董事担任，负责主持 委员会工作；召集人在委员内选举，并报请董事会批准。 第六条 提名委员会每届任期与董事会任期一致，委员任期届满， 连选可以连任。期间如有委员不再担任公司董事职务，自动失去委员 资格，并由董事会根据上述第三至第五条规定补足委员人数。 第七条 提名委员会下设办公室作为日常办事机构 ...

证券代码：000705 证券简称：浙江震元 公告编号：2025-043 浙江震元股份有限公司 关于修订《公司章程》及修订、制定公司制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江震元股份有限公司 2025 年 11 月 28 日第十一届董事会 2025 年第五次临时会议，审议通过《关于修订<公司章程>及其附则的议案》 《关于修订部分上市公司制度的议案》《关于制定<浙江震元股份有限 公司董事、高级管理人员离职管理制度><浙江震元股份有限公司会计 师事务所选聘制度>的议案》等议案，现将相关事项公告如下： 一、修订说明 3、根据证监会最新发布的《上市公司章程指引》进行修改。完善、 修改"股东临时提案权""股东会及董事会职权""独立董事和董事 会专门委员会""内部审计"等内容。 1、根据《中华人民共和国公司法》的相关规定，拟将《公司章程》 《股东大会议事规则》《董事会议事规则》等公司治理相关管理制度 中涉及"股东大会"表述统一规范为"股东会"。 2、根据《中华人民共和国公司法》《关于新<公司法>配套制度规 则实施相关过渡期安排》《上市公司章程指引（20 ...

Group 1 - The core event on November 24 marks a significant "super meeting day" for multiple listed companies in Zhejiang, indicating a collective strategic decision-making process [1][3][4][5] - Companies like Huawai Technology, Anglikang, and Hechuan Technology are holding shareholder meetings to discuss future strategies and governance [1][6] Group 2 - There is a noticeable performance divergence among Zhejiang-listed companies, with Zhejiang Rongtai reporting a revenue of 960 million yuan for Q1-Q3 2025, a year-on-year increase of 18.65%, and a net profit of 203 million yuan, up 22.04% [7][8] - In contrast, Zhejiang Natural reported a revenue decline of 30.38% and a net profit drop of 40.63% for the same period [7][8] Group 3 - Emerging sectors are seeing accelerated investments, with Zhejiang Rongtai focusing on humanoid robot components, which are expected to experience significant growth [9][10] - The company is also involved in the new energy sector, with its mica products being crucial for electric vehicle battery safety, anticipating increased demand due to upcoming regulations [10] Group 4 - Institutional investors are showing strong interest in Zhejiang companies, with Zhejiang Rongtai projected to achieve revenues of 1.423 billion, 2.481 billion, and 4.178 billion yuan from 2025 to 2027, alongside net profits of 277 million, 485 million, and 839 million yuan respectively [11][12] - Zhejiang Pharmaceutical has also attracted attention, with forecasts estimating a net profit of 1.113 billion yuan for 2025 [13] Group 5 - Strategic upgrades are underway among Zhejiang-listed companies, focusing on optimizing corporate governance structures, as seen with Anglikang's adjustments to its supervisory framework [15] - International expansion is being pursued, with Zhejiang Rongtai establishing a production base in Thailand and Zhejiang Natural having subsidiaries in Vietnam and Cambodia [15][16] - Continuous investment in technological innovation is emphasized, with companies like Zhejiang Rongtai and Zhejiang Zhenyuan enhancing their R&D capabilities [16]

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]

Group 1 - The company, Zhejiang Zhenyuan (000705), stated on November 12 that it currently does not produce any weight loss medication products [1] - Zhenyuan Pharmaceutical has no plans for contract manufacturing at this time [1]

Core Viewpoint - Zhejiang Zhenyuan (000705.SZ) currently does not produce any weight loss medication products and has no plans for contract manufacturing [1] Company Summary - The company has confirmed through its interactive platform that it is not involved in the production of weight loss drugs [1] - There are no current plans for contract manufacturing related to weight loss products [1]

Company Overview - Zhejiang Zhenyuan's stock price increased by 2.04% on November 11, reaching 10.02 CNY per share, with a total market capitalization of 3.348 billion CNY [1] - The company has seen a year-to-date stock price increase of 27.64%, with a 5-day increase of 2.98%, a 20-day increase of 5.70%, and a 60-day increase of 5.70% [1] - Zhejiang Zhenyuan has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 21, where it recorded a net buy of -9.6038 million CNY [1] Business Performance - For the period from January to September 2025, Zhejiang Zhenyuan reported a revenue of 1.78 billion CNY, a year-on-year decrease of 37.59%, while the net profit attributable to shareholders was 56.0599 million CNY, reflecting a year-on-year increase of 28.67% [2] - The company's main business segments include retail (45.55%), wholesale (28.75%), industrial preparations (14.08%), raw materials (7.94%), health services (2.88%), and others (0.80%) [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.24% to 35,800, while the average circulating shares per person decreased by 14.70% to 7,877 shares [2] - The company has distributed a total of 228 million CNY in dividends since its A-share listing, with 60.1422 million CNY distributed in the last three years [3] Industry Context - Zhejiang Zhenyuan operates within the pharmaceutical and biological sector, specifically in pharmaceutical commerce and distribution, and is associated with concepts such as cold chain logistics, medical devices, and digital economy [2]